Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Impact of PSMA PET on Prostate Cancer Management

Current Treatment Options in Oncology(2024)10.1007/s11864-024-01181-9Source: DataRank Database

Impact of PSMA PET on Prostate Cancer Management is a research paper published in Current Treatment Options in Oncology (2024). On theSindex it has a DataRank of 0. It has been cited 17 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access17 citations

Download PDF

Cite:

Linked data & code

nct

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (17 grants)Impact (FWCI 4.81)OA: greenTopics (89)IDs (PubMed, PMC, OpenAlex)Annotations (1)SDGs (2)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (10)

Raag Agrawal ORCID,Luca Valle ORCID,Ida Sonni ORCID,Amar U. Kishan ORCID,Matthew B. Rettig ORCID

Live enrichment

PubMed:38270802 PMC:PMC11034977 OpenAlex:https://openalex.org/W4391225346

National Institutes of Health

Grant: T32GM008042

National Institutes of Health

Grant: U2CCA271894

Office of Extramural Research, National Institutes of Health

Grant: P50CA09213

National Institutes of Health,United States

Grant: P30CA016042

U.S. Department of Defense

Grant: W81XWH2210247

U.S. Department of Defense,United States

Grant: W81XWH2210751

NCI NIH HHS

Grant: P50 CA092131

NCI NIH HHS

Grant: T32 CA009213

NCI NIH HHS

Grant: R01 CA270108

National Institutes of Health

Grant: 5T32GM008042-27

Medical Scientist Training Program

National Institutes of Health

Grant: 3P30CA016042-35S3

Cancer Center Support Grant

National Institutes of Health

Grant: 5T32CA009213-27

CANCER BIOLOGY TRAINING GRANT

National Institutes of Health

Grant: 5R01CA270108-02

Germline Determinants of Prostate Cancer Evolution

National Institutes of Health

Grant: 1U2CCA271894-01

Virginia-UCLA-Toronto Biomarker Characterization Center

Simon-Strauss Foundation

Prostate Cancer Foundation Young Investigator Award

UCLA Dr. Allen and Charlotte Ginsburg Fellowship in Precision Genomic Medicine

FWCI

4.81

Citation Percentile

1.0%

Citation Trend

2024

2025

2026

greenLicense: Springer Nature TDM

repositoryhttps://escholarship.org/content/qt3f5607n3/qt3f5607n3.pdf

publisherhttps://link.springer.com/content/pdf/10.1007/s11864-024-01181-9.pdf

publisherhttps://link.springer.com/article/10.1007/s11864-024-01181-9/fulltext.html

repositoryhttps://escholarship.org/uc/item/3f5607n3

Fields of Study

Prostate Cancer Treatment and ResearchProstate Cancer Diagnosis and TreatmentRadiopharmaceutical Chemistry and Applications0302 clinical medicine03 medical and health sciences

MeSH Terms

Positron Emission Tomography Computed TomographyAntigens, SurfaceHumansMaleNeoplasm StagingProspective StudiesProstatic NeoplasmsProstate-Specific AntigenRadiopharmaceuticalsGlutamate Carboxypeptidase II

Keywords

MedicineProstate cancerPet imagingClinical trialMedical physicsManagement of prostate cancerClinical PracticeBiomarkerImaging biomarkerModalitiesPositron emission tomographyNuclear medicineOncologyRadiologyCancerMagnetic resonance imagingInternal medicinePhysical therapyDrug therapyPrognosisProstatic neoplasmsSurgeryRadiotherapyClinical Decision-makingNeoplasm StagingPositron-emission TomographyTheranostic NanomedicineMaleAgingSurface (mesh)Prostate-Specific Antigen (mesh)Health Disparities (rcdc)Prostate Cancer (rcdc)Aging (rcdc)Biomedical Imaging (rcdc)Clinical Research (rcdc)Positron Emission Tomography Computed TomographyMinority HealthProspective Studies32 Biomedical and Clinical Sciences (for-2020)Male (mesh)Cancer (rcdc)Humans (mesh)Bioengineering (rcdc)Health DisparitiesSurface4.2 Evaluation of markers and technologies (hrcs-rac)Antigens, SurfaceBiomedical ImagingMinority Health (rcdc)4.2 Evaluation of markers and technologiesProstatic Neoplasms (mesh)Urologic DiseasesClinical SciencesOncology and Carcinogenesis610BioengineeringClinical Research6163211 Oncology and carcinogenesis (for-2020)HumansOncology & CarcinogenesisAntigensProspective Studies (mesh)3202 Clinical Sciences (for-2020)Biomedical and Clinical SciencesPositron Emission Tomography Computed Tomography (mesh)Cancer (hrcs-hc)Prostate-Specific AntigenRadiopharmaceuticals (mesh)Neoplasm Staging (mesh)Oncology & Carcinogenesis (science-metrix)Urologic Diseases (rcdc)Radiopharmaceuticals

Sustainable Development Goals

SDG 3: 3. Good healthSDG 0: Good health and well-being

Impact of PSMA PET on Prostate Cancer Management

FAIR Checklist

Authors (10)

Funding (17 grants)

Impact

Open Access

Topics

Annotations (Europe PMC)